Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine.

Journal: Briefings in bioinformatics
Published Date:

Abstract

The increase in the expectations of artificial intelligence (AI) technology has led to machine learning technology being actively used in the medical field. Non-negative matrix factorization (NMF) is a machine learning technique used for image analysis, speech recognition, and language processing; recently, it is being applied to medical research. Precision medicine, wherein important information is extracted from large-scale medical data to provide optimal medical care for every individual, is considered important in medical policies globally, and the application of machine learning techniques to this end is being handled in several ways. NMF is also introduced differently because of the characteristics of its algorithms. In this review, the importance of NMF in the field of medicine, with a focus on the field of oncology, is described by explaining the mathematical science of NMF and the characteristics of the algorithm, providing examples of how NMF can be used to establish precision medicine, and presenting the challenges of NMF. Finally, the direction regarding the effective use of NMF in the field of oncology is also discussed.

Authors

  • Ryuji Hamamoto
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan.
  • Ken Takasawa
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Hidenori Machino
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Kazuma Kobayashi
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute.
  • Satoshi Takahashi
    Department of Neurosurgery, University of Tokyo, Tokyo.
  • Amina Bolatkan
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Norio Shinkai
    Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan.
  • Akira Sakai
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Rina Aoyama
    Showa University Graduate School of Medicine School of Medicine.
  • Masayoshi Yamada
    Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. masyamad@ncc.go.jp.
  • Ken Asada
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Masaaki Komatsu
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Koji Okamoto
    National Cancer Center Research Institute.
  • Hirokazu Kameoka
    NTT Communication Science Laboratories.
  • Syuzo Kaneko
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.